HomeCompareTTYP vs ABBV

TTYP vs ABBV: Dividend Comparison 2026

TTYP yields 13.98% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $54.6K in total portfolio value· pulled ahead in Year 6
10 years
TTYP
TTYP
● Live price
13.98%
Share price
$53.00
Annual div
$7.41
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$50.1K
Annual income
$3,325.67
Full TTYP calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — TTYP vs ABBV

📍 ABBV pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTTYPABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TTYP + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TTYP pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TTYP
Annual income on $10K today (after 15% tax)
$1,188.40/yr
After 10yr DRIP, annual income (after tax)
$2,826.82/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $19,040.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TTYP + ABBV for your $10,000?

TTYP: 50%ABBV: 50%
100% ABBV50/50100% TTYP
Portfolio after 10yr
$77.4K
Annual income
$14,525.70/yr
Blended yield
18.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TTYP
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TTYP buys
0
ABBV buys
0
No recent congressional trades found for TTYP or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTTYPABBV
Forward yield13.98%3.12%
Annual dividend / share$7.41$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$50.1K$104.7K
Annual income after 10y$3,325.67$25,725.73
Total dividends collected$23.2K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TTYP vs ABBV ($10,000, DRIP)

YearTTYP PortfolioTTYP Income/yrABBV PortfolioABBV Income/yrGap
1$12,098$1,398.11$11,559$438.51+$539.00TTYP
2$14,526$1,580.80$13,494$640.86+$1.0KTTYP
3$17,316$1,773.84$15,951$945.97+$1.4KTTYP
4$20,505$1,976.28$19,152$1,413.89+$1.4KTTYP
5$24,127$2,187.08$23,443$2,146.38+$684.00TTYP
6← crossover$28,221$2,405.09$29,391$3,321.96$1.2KABBV
7$32,826$2,629.16$37,948$5,265.87$5.1KABBV
8$37,982$2,858.07$50,795$8,596.74$12.8KABBV
9$43,731$3,090.63$71,034$14,549.41$27.3KABBV
10$50,118$3,325.67$104,715$25,725.73$54.6KABBV

TTYP vs ABBV: Complete Analysis 2026

TTYPStock

Trinity Petroleum Trust operates as a royalty trust that owns oil and gas properties in the United States. The company is based in Austin, Texas.

Full TTYP Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TTYP vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TTYP vs SCHDTTYP vs JEPITTYP vs OTTYP vs KOTTYP vs MAINTTYP vs JNJTTYP vs MRKTTYP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.